[
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Thursday when compared to competitors",
    "summary": "AbbVie Inc. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=02881869c76aa4f5a85071660c37d10b9813f5d0bb15e9045646e26b61afa895",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734626040,
      "headline": "AbbVie Inc. stock underperforms Thursday when compared to competitors",
      "id": 132064987,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=02881869c76aa4f5a85071660c37d10b9813f5d0bb15e9045646e26b61afa895"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie's atogepant and onabotulinumtoxinA receive strong recommendations in the newly updated Canadian Headache Society (CHS) Migraine Prevention Guideline",
    "summary": "AbbVie (NYSE: ABBV) announced today that atogepant and onabotulinumtoxinA have received strong recommendations in the newly updated CHS Migraine Prevention Guideline: atogepant is strongly recommended in the treatment of episodic and chronic migraine, and onabotulinumtoxinA, in the treatment of chronic migraine (please refer to the guideline for the full recommendations). The 2024 version marks a crucial step forward in equipping healthcare professionals with the most current, evidence-based rec",
    "url": "https://finnhub.io/api/news?id=adbeaf88ef68779e110af0cb41b503c0d5c1d2a897d12b5019a2439031d58f07",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734613200,
      "headline": "AbbVie's atogepant and onabotulinumtoxinA receive strong recommendations in the newly updated Canadian Headache Society (CHS) Migraine Prevention Guideline",
      "id": 132057952,
      "image": "https://media.zenfs.com/en/cnwgroup.com/7ce5a1b5322122bc0323116739cb329f",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) announced today that atogepant and onabotulinumtoxinA have received strong recommendations in the newly updated CHS Migraine Prevention Guideline: atogepant is strongly recommended in the treatment of episodic and chronic migraine, and onabotulinumtoxinA, in the treatment of chronic migraine (please refer to the guideline for the full recommendations). The 2024 version marks a crucial step forward in equipping healthcare professionals with the most current, evidence-based rec",
      "url": "https://finnhub.io/api/news?id=adbeaf88ef68779e110af0cb41b503c0d5c1d2a897d12b5019a2439031d58f07"
    }
  },
  {
    "ts": null,
    "headline": "2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond",
    "summary": "Whatever the answer is, it probably won't be dividend investing.  Let's consider two income-focused corporations whose shares are worth holding on to well beyond next year: AbbVie (NYSE: ABBV) and Abbott Laboratories (NYSE: ABT).  AbbVie, a former division of Abbott Laboratories, became a stand-alone company in 2013.",
    "url": "https://finnhub.io/api/news?id=f632dd48e8fe696ce52c4f3aa1c835a1e1cc2a98041ed2d2398f4e37432c52bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734606000,
      "headline": "2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond",
      "id": 132057954,
      "image": "https://g.foolcdn.com/editorial/images/800762/nurse-holding-patients-hands.jpg",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Whatever the answer is, it probably won't be dividend investing.  Let's consider two income-focused corporations whose shares are worth holding on to well beyond next year: AbbVie (NYSE: ABBV) and Abbott Laboratories (NYSE: ABT).  AbbVie, a former division of Abbott Laboratories, became a stand-alone company in 2013.",
      "url": "https://finnhub.io/api/news?id=f632dd48e8fe696ce52c4f3aa1c835a1e1cc2a98041ed2d2398f4e37432c52bb"
    }
  },
  {
    "ts": null,
    "headline": "Impax Small Cap Fund Q3 2024 Commentary",
    "summary": "The Impax Small Cap Fund outperformed its benchmark in Q3 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=ab72bcbc7d1f69948809802b9801ce65775db233e4bdca3dd409ca6218949ce7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734603300,
      "headline": "Impax Small Cap Fund Q3 2024 Commentary",
      "id": 132052035,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2162096672/image_2162096672.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "The Impax Small Cap Fund outperformed its benchmark in Q3 2024. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=ab72bcbc7d1f69948809802b9801ce65775db233e4bdca3dd409ca6218949ce7"
    }
  },
  {
    "ts": null,
    "headline": "Is AbbVie Inc. (ABBV) the Safest Dividend Stock to Invest In Now?",
    "summary": "We recently compiled a list of the Retirement Stock Portfolio: 7 Safe Dividend Stocks To Invest In. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other dividend stocks. As investors near retirement, achieving financial stability becomes a top priority. Among the various investment choices, steady […]",
    "url": "https://finnhub.io/api/news?id=cfdd51722f0324b8d925b5e4e3c7d78e2ec1773ff9feace015978c3a57867ffe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734601253,
      "headline": "Is AbbVie Inc. (ABBV) the Safest Dividend Stock to Invest In Now?",
      "id": 132057955,
      "image": "https://s.yimg.com/ny/api/res/1.2/m1YYSOl9HO_x0LHuYGlC8Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the Retirement Stock Portfolio: 7 Safe Dividend Stocks To Invest In. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other dividend stocks. As investors near retirement, achieving financial stability becomes a top priority. Among the various investment choices, steady […]",
      "url": "https://finnhub.io/api/news?id=cfdd51722f0324b8d925b5e4e3c7d78e2ec1773ff9feace015978c3a57867ffe"
    }
  },
  {
    "ts": null,
    "headline": "Retirement-Ready Income: 5 Dividend Gems I'd Buy If I Were 65",
    "summary": "Retirement-Ready Income: 5 Dividend Gems I'd Buy If I Were 65",
    "url": "https://finnhub.io/api/news?id=843aed1546178ab00571353f3e470d2ab8399d6345b677cbb9b438e868bfaaab",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734593400,
      "headline": "Retirement-Ready Income: 5 Dividend Gems I'd Buy If I Were 65",
      "id": 132050154,
      "image": "",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=843aed1546178ab00571353f3e470d2ab8399d6345b677cbb9b438e868bfaaab"
    }
  }
]